keyword
MENU ▼
Read by QxMD icon Read
search

Dysport

keyword
https://www.readbyqxmd.com/read/29569830/the-efficacy-and-complications-of-a-new-technique-of-abobotulinum-toxin-a-dysport-injection-in-patients-with-glabellar-lines
#1
Esmat Karbassi, Nouzar Nakhaee, Maryam Zamanian
BACKGROUND: Abobotulinum- toxin A is used extensively for the treatment of frown (glabellar) lines. AIMS: The aim of this study was to evaluate the efficacy and complications of a new injection technique and to assess the amount of satisfaction in patients with the frown lines. METHODS: This cross-sectional study was conducted in 104 patients with moderate-to-severe glabellar lines. In the new technique by reassessing the responsible anatomic muscles of wrinkles, we tried to modify the injection technique of Abobotulinum-toxin A to yield more favorable results...
March 23, 2018: Journal of Cosmetic Dermatology
https://www.readbyqxmd.com/read/29506030/perioral-rejuvenation-a-prospective-quantitative-dynamic-three-dimensional-analysis-of-a-dual-modality-treatment
#2
Catherine S Chang, Brian L Chang, Michael Lanni, Anthony J Wilson, Jacob Beer, Ivona Percec
Background: The perioral region is the most dynamic anatomic area of the face and subject to complex and dramatic changes during aging. Successful treatment for perioral rejuvenation has yet to be identified, and prior studies have reported only subjective outcomes. Objectives: The purpose of this study is to utilize our validated dynamic three-dimensional imaging technology to determine whether conservative neuromodulation combined with hyaluronic acid filler volumization can decrease perioral strain and increase volume with significant patient satisfaction...
March 1, 2018: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/29452742/to-switch-from-botox-to-dysport-in-children-with-cp-a-real-world-dose-conversion-cost-effectiveness-study
#3
Kristina Tedroff, Gustaf Befrits, Carl Johan Tedroff, Stefan Gantelius
BACKGROUND AND OBJECTIVES: Children with cerebral palsy (CP) are routinely treated with botulinum toxin A (BoNT-A). Two non dose-equivalent and differently priced products, Botox and Dysport are used. Depending on the conversion one of the products is considerably cheaper. However, the dose conversion factors studied to date have varied widely and relevant studies have not included children. Our objective here was to compare the efficacy and health economics of the switch from Botox to Dysport in children with CP when conversion was set to 1:2...
February 3, 2018: European Journal of Paediatric Neurology: EJPN
https://www.readbyqxmd.com/read/29408357/evidence-on-botulinum-toxin-in-selected-disorders
#4
Elina Zakin, David Simpson
Botulinum toxin (BoNT) is a neurotoxin produced by the bacteria Clostridium botulinum that has become widely used for various neurologic indications. The four toxin formulations currently available for use in the United States (approved by the Food and Drug Administration) are onabotulinumtoxinA (Botox® ), abobotulinumtoxinA (Dysport® ), incobotulinumtoxinA (Xeomin® ), and rimabotulinumtoxinB (Myobloc® ). While the FDA-approved labels indicate that potency conversions should not be done, literature supports relative dose equivalents of approximately 1:1:2-4:50-100, respectively...
February 3, 2018: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/29384393/intralesional-botulinum-toxin-a-injection-for-the-treatment-of-multiple-eccrine-hidrocystomas
#5
Mehdi Gheisari, Behnaz Hamedani, RezaM Robati, Nikoo Mozafari
BACKGROUND: Multiple eccrine hidrocystomas (MEH) are benign cystic lesions of the sweat gland ducts. They are characterized by translucent, skin-colored or bluish dome-shaped papules on the face, causing cosmetic concern. Recently, botulinum toxin-A, because of its antiperspirant properties, has been used to treat facial MEH. However, there are only some case reports in the literature. OBJECTIVE: Here, we conducted a prospective study to assess the efficacy and safety of intralesional injection of botulinum toxin-A (Dysport) for the treatment of MEH...
January 31, 2018: Journal of Cosmetic and Laser Therapy: Official Publication of the European Society for Laser Dermatology
https://www.readbyqxmd.com/read/29376224/long-term-efficacy-of-botulinum-neurotoxin-a-treatment-for-essential-blepharospasm
#6
Seunghyun Lee, Sangrye Park, Helen Lew
PURPOSE: In the present study, we investigated the treatment efficacy and clinical outcomes of botulinum neurotoxin-A (BoNT-A) administered for longer than 5 years to patients with essential blepharospasm. METHODS: We retrospectively reviewed 19 patients (male : female = 8 : 11) diagnosed with essential blepharospasm between March 2006 and July 2016 who underwent BoNT-A injections for over 5 years and were followed. Efficacy of 297 injections of Botox (n = 162), Meditoxin (n = 75), Hugel-tox (n = 40), or Dysport (n = 20) was based on the symptom improvement score at the final injection (-1, worse; 0, same; 1, better)...
January 24, 2018: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/29343142/a-500-u-2-ml-dilution-of-abobotulinumtoxina-vs-placebo-randomized-study-in-cervical-dystonia
#7
Mark F Lew, Allison Brashear, Khashayar Dashtipour, Stuart Isaacson, Robert A Hauser, Pascal Maisonobe, Daniel Snyder, William Ondo
Purpose/aim: AbobotulinumtoxinA (Dysport®, Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ, USA) is an acetylcholine release inhibitor and a neuromuscular blocking agent. The United States prescribing information for abobotulinumtoxinA previously indicated only one dilution for cervical dystonia: 500 U/1 mL. Clinical trial data supporting a larger volume with a 500 U/2 mL dilution would offer clinicians flexibility with injection volume to better meet patient needs. MATERIALS AND METHODS: We conducted a 12-week, phase 3b, multicenter, randomized, double-blind, placebo-controlled trial (NCT01753310)...
January 17, 2018: International Journal of Neuroscience
https://www.readbyqxmd.com/read/29230798/botulinum-toxin-type-a-therapy-for-cervical-dystonia
#8
REVIEW
Mafalda Castelão, Raquel E Marques, Gonçalo S Duarte, Filipe B Rodrigues, Joaquim Ferreira, Cristina Sampaio, Austen P Moore, João Costa
BACKGROUND: This is an update of a Cochrane Review first published in 2005. Cervical dystonia is the most common form of focal dystonia and is a highly disabling movement disorder characterised by involuntary, usually painful, head posturing. Currently, botulinum toxin type A (BtA) is considered the first line therapy for this condition. OBJECTIVES: To compare the efficacy, safety, and tolerability of botulinum toxin type A (BtA) versus placebo in people with cervical dystonia...
December 12, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29229221/intravesical-electromotive-botulinum-toxin-type-a-administration-for-management-of-urinary-incontinence-secondary-to-neuropathic-detrusor-overactivity-in-children-long-term-follow-up
#9
Seyedeh-Sanam Ladi-Seyedian, Lida Sharifi-Rad, Abdol-Mohammad Kajbafzadeh
OBJECTIVE: To investigate the long-term efficacy and success rate of intravesical electromotive botulinum toxin type A (BoNTA) "Dysport" administration in patients with myelomeningocele who had urinary incontinence due to neuropathic detrusor overactivity (NDO). MATERIALS AND METHODS: Twenty-four patients with myelomeningocele (mean age: 9 ± 3.6 years, range: 3-16) were included in the study and followed up for 6 years. Using an electrode bladder catheter, 10 IU/kg of Dysport (BoNTA) was inserted into the bladder for electromotive drug administration (EMDA) without anesthesia on outpatient basis...
December 8, 2017: Urology
https://www.readbyqxmd.com/read/29093068/efficacy-and-safety-of-abobotulinumtoxina-in-spastic-lower-limb-randomized-trial-and-extension
#10
RANDOMIZED CONTROLLED TRIAL
Jean-Michel Gracies, Alberto Esquenazi, Allison Brashear, Marta Banach, Serdar Kocer, Robert Jech, Svetlana Khatkova, Ján Benetin, Michele Vecchio, Peter McAllister, Jan Ilkowski, Stanislaw Ochudlo, France Catus, Anne Sophie Grandoulier, Claire Vilain, Philippe Picaut
OBJECTIVE: To demonstrate single abobotulinumtoxinA injection efficacy in lower limb vs placebo for adults with chronic hemiparesis and assess long-term safety and efficacy of repeated injections. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, single-cycle study followed by a 1-year open-label, multiple-cycle extension, adults ≥6 months after stroke/brain injury received one lower limb injection (abobotulinumtoxinA 1,000 U, abobotulinumtoxinA 1,500 U, placebo) followed by ≤4 open-label cycles (1,000, 1,500 U) at ≥12-week intervals...
November 28, 2017: Neurology
https://www.readbyqxmd.com/read/29053134/-conversion-ratio-between-different-botulinum-neuroprotein-product-in-neurological-practice
#11
REVIEW
O R Orlova, S L Timerbaeva, S E Khatkova, E V Kostenko, D A Krasavina, D V Zakharov
Despite nearly 30 years of experience in the application of botulinum toxin type A (BTA) in clinical practice, many fundamental questions of therapy remain valid. There are 5 botulinum toxin type A used for neurological indications in the Russian Federation in 2017. They contain different number of active neuroprotein (150 kDa) in a therapeutic dose of the drug that may have a potential impact on the efficacy and duration of action. The current SmPC of each BTA stated that the unit of activity is unique and can not be compared with any other BTA...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29040367/forehead-lift-using-botulinum-toxin
#12
Sarit Cohen, Ofir Artzi, Lior Heller
Background: The principle of dynamic muscular activity affecting eyebrow height and shape is well known. We postulate that similarly, dynamics of the fronto-galea-occipital muscles affect forehead height. Objectives: To present a forehead lift technique using Botulinum toxin injection and evaluate its clinical efficacy and safety. Methods: Twenty-nine female patients comprised the study group. Forty units of prepared abobutolinumtoxinA (Dysport, 10 U/0...
October 10, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28915291/cosmetic-practitioners-take-huge-risks-purchasing-and-administering-illegal-botulinum-toxin-drug-products
#13
Sheldon Bradshaw
In their article "Importing Injectables" in the September 2014 issue of the Journal of Drugs in Dermatology, Dr. Kenneth Beer and Karen Rothschild highlighted the possible harm to patients and practitioners from the use of unapproved botulinum toxin products - eg, Botox, Dysport, Xeomin, and Myobloc - and other cosmetic prescription drug products purchased from foreign or unlicensed suppliers.1 In the intervening years, the accuracy of their critique has been repeatedly demonstrated, as the dangers to patients' health, as well as to cosmetic practitioners' liberty, has only increased...
September 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28904941/is-there-any-relationship-between-bladder-trabeculation-and-efficacy-and-safety-of-intravesical-botulinum-toxin-a-injection-in-refractory-idiopathic-overactive-bladder-women
#14
Mahtab Zargham, Shideh Abedi, Farshid Alizadeh, Mohamad Hatef Khorami, Mehrdad Mohamadi, Faranak Bahrami, Farzaneh Sharifiaghdas, Hamid Mazdak
BACKGROUND: Intradetrusor injection of botulinum toxin A (BTX-A) might serve as a minimally invasive substitute in patients with refractory idiopathic overactive bladder (RIOAB). The aim of this study was to evaluate the clinical outcomes related to two different doses of abo-BTX-A (AboBTX-A) in patients with RIOAB. MATERIALS AND METHODS: This prospective clinical trial was performed on 55 women with RIOAB. After determination of trabeculation grade, 300 (no or mild) or 500 (moderate or severe) unit of AboBTX-A (Dysport) was intravesicaly injected...
2017: Advanced Biomedical Research
https://www.readbyqxmd.com/read/28669425/-treatment-of-hailey-hailey-disease-with-botulinic-toxin-a-retrospective-study-of-8-cases
#15
L Dousset, A Pham-Ledard, M-S Doutre, M Beylot-Barry, O Cogrel
BACKGROUND: Hailey-Hailey disease (HHD) is characterised by episodes of weeping erythematous lesions, particularly in areas subject to friction or maceration. Treatment is complex. The value of botulinum toxin has been demonstrated in several studies and in individual cases. AIM: To report clinical and progressive data for 8 patients treated for HHD with injections of botulinum toxin A (BTX-A), following the failure of several other therapeutic approaches. PATIENTS AND METHODS: Eight patients (three males and five females), of median age 52...
October 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28657917/patient-registry-of-spasticity-care-world-data-analysis-based-on-physician-experience
#16
MULTICENTER STUDY
Alberto Esquenazi, Stella Lee, Nathaniel Mayer, Roser Garreta, Atul Patel, Elie Elovic, Stephen Koelbel, Gerard Francisco, Iris Reuter
OBJECTIVE: The aim of the study was to report physician experience-based "real-world" treatment patterns with botulinum toxin type A in patients with stroke and traumatic brain injury. DESIGN: A prospective, multicenter, international observational registry design was used. RESULTS: Six hundred twenty-seven participants with stroke and 132 participants with traumatic brain injury were assessed and treated by 17 more experienced physicians and 12 less experienced physicians...
December 2017: American Journal of Physical Medicine & Rehabilitation
https://www.readbyqxmd.com/read/28639368/botulinum-toxin-state-of-the-art
#17
REVIEW
Joseph Jankovic
Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions...
August 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28634000/dose-dependent-effects-of-abobotulinumtoxina-dysport-on-spasticity-and-active-movements-in-adults-with-upper-limb-spasticity-secondary-analysis-of-a-phase-3-study
#18
Michael W O'Dell, Allison Brashear, Robert Jech, Thierry Lejeune, Philippe Marque, Djamel Bensmail, Ziyad Ayyoub, David M Simpson, Magali Volteau, Claire Vilain, Philippe Picaut, Jean Michel Gracies
BACKGROUND: AbobotulinumtoxinA has beneficial effects on spasticity and active movements in hemiparetic adults with upper limb spasticity (ULS). However, evidence-based information on optimal dosing for clinical use is limited. OBJECTIVE: To describe joint-specific dose effects of abobotulinumtoxinA in adults with ULS. DESIGN: Secondary analysis of a phase 3 study (NCT01313299). SETTING: Multicenter, international, double-blind, placebo-controlled clinical trial...
January 2018: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/28625615/efficacy-and-safety-of-abobotulinumtoxina-dysport-for-the-treatment-of-hemiparesis-in-adults-with-upper-limb-spasticity-previously-treated-with-botulinum-toxin-subanalysis-from-a-phase-3-randomized-controlled-trial
#19
Christina Marciniak, Peter McAllister, Heather Walker, Allison Brashear, Steven Edgley, Thierry Deltombe, Svetlana Khatkova, Marta Banach, Fatma Gul, Claire Vilain, Philippe Picaut, Anne-Sophie Grandoulier, Jean-Michel Gracies
OBJECTIVE: To assess the efficacy and safety of abobotulinumtoxinA in adults with upper limb spasticity previously treated with botulinum toxin A (BoNT-A). DESIGN: A post hoc analysis from a Phase 3, prospective, double-blind, randomized, placebo-controlled study (NCT01313299). SETTING: A total of 34 neurology or rehabilitation clinics in 9 countries. PARTICIPANTS: Adults aged 18-80 years with hemiparesis, ≥6 months after stroke or traumatic brain injury...
December 2017: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/28623614/abobotulinumtoxina-a-review-in-pediatric-lower-limb-spasticity
#20
REVIEW
Yahiya Y Syed
AbobotulinumtoxinA (Dysport® ) is currently the only botulinum toxin A formulation approved by the US FDA for the treatment of lower limb spasticity in pediatric patients aged ≥2 years. Intramuscular abobotulinumtoxinA was approved based on the results of a pivotal phase 3 trial in children with lower limb spasticity due to cerebral palsy. In this trial, a single treatment cycle with abobotulinumtoxinA 10-15 U/kg/leg injected into the gastrocnemius and soleus muscles significantly improved ankle plantar flexor muscle tone (primary endpoint), with abobotulinumtoxinA recipients showing a significant response to treatment relative to placebo...
August 2017: Paediatric Drugs
keyword
keyword
9455
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"